Defining an Optimized Workflow for Enriching and Analyzing Residual Tumor Populations Using Intracellular Markers.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 23 06 2023
revised: 12 12 2023
accepted: 11 01 2024
pubmed: 28 1 2024
medline: 28 1 2024
entrez: 27 1 2024
Statut: ppublish

Résumé

Tumor relapse is well recognized to arise from treatment-resistant residual populations. Strategies enriching such populations for in-depth downstream analyses focus on tumor-specific surface markers; however, enrichment using intracellular biomarkers remains challenging. Using B-cell lymphoma as an exemplar, we demonstrate feasibility to enrich B-cell lymphoma 2 (BCL2)

Identifiants

pubmed: 38280422
pii: S1525-1578(24)00008-4
doi: 10.1016/j.jmoldx.2024.01.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-256

Subventions

Organisme : Cancer Research UK
ID : 26819
Pays : United Kingdom

Informations de copyright

Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Eve M Coulter (EM)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Electronic address: e.coulter@qmul.ac.uk.

Findlay Bewicke-Copley (F)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Maximilian Mossner (M)

Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom; Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Trevor A Graham (TA)

Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom; Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Jude Fitzgibbon (J)

Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; AstraZeneca, Waltham, Massachusetts.

Jessica Okosun (J)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Electronic address: j.okosun@qmul.ac.uk.

Classifications MeSH